Literature DB >> 9416983

Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals.

J S Jensen1, B Feldt-Rasmussen, K Borch-Johnsen, P Clausen, M Appleyard, G Jensen.   

Abstract

Microalbuminuria has been proposed as a potential atherosclerotic risk factor in hypertensive individuals. The aim of this cross-sectional population study was to analyse whether microalbuminuria is related to a higher prevalence of cardiovascular disease, and a more atherogenic risk profile, and reversely related to the use of antihypertensive drugs. In a major health screening at the State University Hospital in Copenhagen, including urinary albumin excretion, glomerular filtration rate, blood pressure (BP), electrocardiogram, body mass index, plasma lipoproteins, fibrinogen, and albumin, and information regarding a history of acute myocardial infarction, smoking, and antihypertensive drugs, 1254 participants without diabetes mellitus or renal/urinary tract disease had arterial hypertension. Age range was 30-70 years. Microalbuminuria (nocturnal urinary albumin excretion >15 microg/min) occurred in 5%, and cardiovascular disease (previous acute myocardial infarction or electrocardiographic Q-waves) also in 5% of the study population. Microalbuminuric hypertensive subjects were characterized by higher age and systolic BP, and a male predominance, as compared to normoalbuminuric hypertensive subjects. The frequency of cardiovascular disease was similar in the two groups. In contrast, when analysed as a continuous variable, a one unit increase in the logarithmically transformed urinary albumin excretion significantly increased the likelihood of cardiovascular disease (odds ratio [95% confidence interval] 1.32 (1.02-1.70); P < 0.05), and this relation was independent of age, sex, and conventional atherosclerotic risk factors. Participants who were effectively treated with antihypertensive drugs did not have a lower urinary albumin excretion than insufficiently treated or untreated participants. It is concluded that slightly elevated albumin excretion in the urine is not only a pressure-dependent functional phenomenon in the glomerular vessel walls, but associated with permanent atherosclerotic abnormalities in the entire vascular system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416983     DOI: 10.1038/sj.jhh.1000459

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.

Authors:  Taco B M Monster; Wilbert M T Janssen; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

3.  The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate.

Authors:  Jarir Atthobari; Ron T Gansevoort; Sipke T Visser; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

Review 4.  Gestational diabetes: implications for cardiovascular health.

Authors:  Shannon D Sullivan; Jason G Umans; Robert Ratner
Journal:  Curr Diab Rep       Date:  2012-02       Impact factor: 4.810

5.  Overview of the i-SEARCH Global Study : Cardiovascular Risk Factors and Microalbuminuria in Hypertensive Individuals.

Authors:  Michael Böhm; Martin Thoenes; Nicolas Danchin; Jan C Reil; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

6.  A multicenter cohort study of primary hypertension in Korea: study design and interim analysis of the Korean registry of target organ damage in hypertension (KorHR).

Authors:  Suk-Won Choi; Seong Woo Han; Jong Sun Ok; Byung-Su Yoo; Mi-Seung Shin; Sung Ha Park; Kyu-Hyung Ryu
Journal:  Clin Hypertens       Date:  2017-08-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.